head and neck cancer

Step closer race run

Biotech

Immutep's LAG-3 agent posts 'impressive' survival data

Immutep suggests that a high unmet need for first-line, PD-L1-negative HNSCC could potentially pave eftilagimod a path to approval.

Angus Liu May 5, 2025 10:37am

Hiker having trouble climbing mountain

ALX Oncology doubles down as lead asset fails 2 phase 2 trials

Apr 25, 2025 2:25pm

Flexibility and adaptation concept Arrows on cubes following a flexible path

'One of the lucky few': Bicara CEO on last year's $326M IPO

Apr 14, 2025 3:59pm

White arrow on a road pointing to the rising sun

Avacta hits 10% response rate, adds peptide-drug conjugate arms

Jan 16, 2025 8:51am

An arrow incrementally going up stairs before pointing straight up Blue background

Merus touts cancer drug's strong profile with new data drop

Dec 2, 2024 11:59am

share price stock stock price shares falling falling

Pyxis' shares fall on lukewarm early ADC results in solid tumors

Nov 21, 2024 2:30pm